In addition, a subset of triple-negative breast cancers features the deleterious expression of ER, PR, and HER2 and has a high risk of early recurrence and mortality compared with other molecular subtypes [6, 7]. This evidence concerns the gene ESR1 and triple-negative breast carcinoma.